Stephen Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Post PACIFIC outcomes
Of 190 patientss receiving durvalumab consolidation post chemoradiation for NSCLC:
- 91 patients recurred,
- mPFS2 7.9m,
- mOS2 12.1m.
And the most common sites of distant spread were brain, bone, and liver.”
Title: Outcomes and Treatment Patterns for Recurrence Following Concurrent Chemoradiation and Consolidation Durvalumab in Locally Advanced, Unresectable NSCLC: A Multi-Center Study
Authors: Richard D. Hall, Philip Young, John Sharp, Kenan Michaels, Kylie Fultineer, James M. Larner, Marie C. Thomas, Alia C. Lynch, Mu-Hsun Chen, Hong Zhu, Mingjia Li, Logan Roof, Kai He, Peter Shields, Jacob Kaufman, Regan Memmott, Asrar Alahmadi, David P. Carbone, Gregory A. Otterson, Carolyn J. Presley, Karl Haglund, Jeremy Brownstein, Dwight H. Owen, Ryan D. Gentzler.
Read the full article.
You can also explore:
